-
Lorcaserin submitted for FDA review, FDA advisory panel votes against phentermine/topiramate, mixed vote on rosiglitazone, advisory panel votes to remove breast cancer indication from bevacizumab labeling, no increase in seizures found with DTaP vaccine, new REMS for quinine.
-
-
There are several forms of amyloidosis, each with distinct patterns of protein deposition and resulting clinical presentations.
-
A 31-year-old g1p0 caucasian woman in the seventh month of pregnancy is referred for management of her T2N0Mx "triple-negative" breast cancer.
-
-
Hepatitis B virus (HBV) reactivation after rituximab or other immune suppressive therapies may lead to serious adverse outcomes. The authors retrospectively reviewed HBV serology of CD20 positive B-cell lymphoma without active HBV (i.e., negative HBsAg) before and after rituximab. Of the 230 tested, 56 (24%) were anti-HBc positive; the five cases of HBV reactivation all occurred in these 56 patients. Moreover, four of the five were anti-HBs negative (a.k.a, isolated anti-HBc). All received entacavir with the only HBV complication of transaminitis. None of the anti-HBc negative patients reactivated. Isolated anti-HBc, particularly lacking anti-HBs, may be at heightened risk of HBV reactivation after rituximab.
-
-
-
In a multinational trial of erlotinib (Tarceva®) for patients with advanced NSCLC following conventional chemotherapy, improved progression-free and overall survival were demonstrated. The improvement was approximately one week for PFS and one month for OS. However, for the subset with demonstrable activating mutations in the EGFR gene, the benefit of erlotinib treatment was more substantial.
-
Breast cancer occurs in approximately 1 in 100,000 men each year, a rate that is slightly less than 1% of that in women.